Metabolic Reprogramming and Microenvironment in Pancreatic Adenocarcinoma

Recruiting now

Conditions studied: Pancreatic Adenocarcinoma Metastatic

In brief

The present project aims to elucidate the metabolic interactions within the tumor microenvironment of pancreatic adenocarcinoma, both in the primary tumor and in hepatic and pulmonary metastatic sites, as well as in circulating blood biomarkers. Deciphering these complex interactions aims to identify exploitable vulnerabilities for predicting treatment efficacy or for guiding therapeutic strategies.

Key facts

Study ID

NCT07664891

Run by

Institut Paoli-Calmettes

People needed

64

Starts

2025-09-11

Expected to finish

2028-09-01

Last updated by the study team

2026-06-24

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Age > 18 years
• Signed written informed consent specific to the PROMETAP study
• Affiliation with a social security system
• Treatment and follow-up performed at the Institut Paoli-Calmettes
• Metastatic PDAC requiring biopsy as part of routine care (group1 and 2)
• Prior treatment:
• No previous chemotherapy for the "initial" group
• No prior chemotherapy in the metastatic setting for the "Metastatic Relapse" group
• Eligible for chemotherapy (ECOG < 2)
• Non-Inclusion Criteria:
• Contraindication to biopsy of the pancreatic tumor or a hepatic or pulmonary metastasis (group 1 and 2)
• Absence of a metastasis accessible to biopsy (group1 and 2)
• Concurrent treatment for another active cancer
• Pregnant or breastfeeding women
• Patients in emergency situations
• Adult individuals under legal protection (guardianship, trusteeship, judicial protection) or unable to provide informed consent

Where it is running

• Institut Paoli-Calmettes — Marseille, France (enrolling)

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.